StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories non-GAAP Adjusted Research & Development Expense ($M) ($M)

Form 8-K Non-GAAP Reconciliation Tables

QuarterlyAnnual
Latest, FY2025
2,830
Period ended Dec 31, 2025
Change on a year earlier
+4.7%
2,704 in FY2024
History
12 years
Since FY2014
Sources
11
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Adjusted Research & Development Expense ($M) ($M)Year on yearSource
FY2025Dec 31, 20252,830+4.7%SEC Filing (0001628280-26-002982) ↗
FY2024Dec 31, 20242,704+7.3%SEC Filing (0001628280-26-002982) ↗
FY2023Dec 31, 20232,519-3.3%SEC Filing (0001628280-25-002092) ↗
FY2022Dec 31, 20222,606-1.1%SEC Filing (0001628280-24-002009) ↗
FY2021Dec 31, 20212,636+14.9%SEC Filing (0001628280-23-001516) ↗
FY2020Dec 31, 20202,295+2.4%SEC Filing (0001104659-22-007648) ↗
FY2019Dec 31, 20192,242+1.3%SEC Filing (0001104659-21-007942) ↗
FY2018Dec 31, 20182,213+9.3%SEC Filing (0001104659-20-005717) ↗
FY2017Dec 31, 20172,024+50.5%SEC Filing (0001104659-19-002848) ↗
FY2016Dec 31, 20161,345+1.9%SEC Filing (0001104659-18-003691) ↗
FY2015Dec 31, 20151,320+3.7%SEC Filing (0001104659-17-003920) ↗
FY2014Dec 31, 20141,273–SEC Filing (0001104659-16-091861) ↗

Cite this data

StockData. (2026). Abbott Laboratories Non-GAAP Adjusted Research & Development Expense ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ng-rd

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.